Limits...
An inexpensive, fast and sensitive quantitative lateral flow magneto-immunoassay for total prostate specific antigen.

Barnett JM, Wraith P, Kiely J, Persad R, Hurley K, Hawkins P, Luxton R - Biosensors (Basel) (2014)

Bottom Line: A detection limit of 0.8 ng/mL was achieved for total PSA using the RCM and is at clinically significant concentrations.The RCM has the potential to be modified to quantify multiple analytes in this format.This research shows promise for the development of an inexpensive device capable of quantifying multiple analytes at the point-of-care using a magneto-immunoassay in lateral flow format.

View Article: PubMed Central - PubMed

Affiliation: Institute of Bio-Sensing Technology, University of the West of England, Bristol, BS16 1QY, UK; E-Mails: jackie.barnett@uwe.ac.uk (J.M.B.); patrickwraith@blueyonder.co.uk (P.W.); janice.kiely@uwe.ac.uk (J.K.); hp@hphawkins.com (P.H.).

ABSTRACT
We describe the detection characteristics of a device the Resonant Coil Magnetometer (RCM) to quantify paramagnetic particles (PMPs) in immunochromatographic (lateral flow) assays. Lateral flow assays were developed using PMPs for the measurement of total prostate specific antigen (PSA) in serum samples. A detection limit of 0.8 ng/mL was achieved for total PSA using the RCM and is at clinically significant concentrations. Comparison of data obtained in a pilot study from the analysis of serum samples with commercially available immunoassays shows good agreement. The development of a quantitative magneto-immunoassay in lateral flow format for total PSA suggests the potential of the RCM to operate with many immunoassay formats. The RCM has the potential to be modified to quantify multiple analytes in this format. This research shows promise for the development of an inexpensive device capable of quantifying multiple analytes at the point-of-care using a magneto-immunoassay in lateral flow format.

No MeSH data available.


Photograph of the total PSA lateral flow assay.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4264355&req=5

biosensors-04-00204-f004: Photograph of the total PSA lateral flow assay.

Mentions: A photograph showing the brown test and control lines produced by the captured PMPs in the lateral flow assay for at a range of concentrations of PSAT is shown in Figure 4. The voltage change at the test and control line for each concentration of total PSA was determined. Results were expressed as the mean ratio of the test/control line and were plotted against PSA concentration in ng/mL, see Figure 5. A linear response was observed for total PSA assays over the clinically relevant range 0.8–10 ng/mL with a limit of detection based on the IUAPC definition ×2 standard deviations of the negative control of 0.8 ng/mL. This is equivalent to previous data obtained for the quantification of PSA in solution using the RCM [26]. The graph shows a comparison of measurements made by optical means and using the RCM. The variability in individual data values (see standard deviation error bars) was much greater in the RCM measurements than in the scanning densitometer measurements. This probably relates to the positioning of the test and control lines in relation to the sensor coils. The sensitivity to changes in concentration of PSAT was greater using the RCM, this may be because this device quantifies all PMPs present within the entire test or control lines in contrast to the scanning densitometer which detects only those PMPs present at the surface of the strip. For PSAT quantification the sensitivity of the assay is very important, as even a modest increase in PSAT concentration over time can be indicative of disease progression [27].


An inexpensive, fast and sensitive quantitative lateral flow magneto-immunoassay for total prostate specific antigen.

Barnett JM, Wraith P, Kiely J, Persad R, Hurley K, Hawkins P, Luxton R - Biosensors (Basel) (2014)

Photograph of the total PSA lateral flow assay.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4264355&req=5

biosensors-04-00204-f004: Photograph of the total PSA lateral flow assay.
Mentions: A photograph showing the brown test and control lines produced by the captured PMPs in the lateral flow assay for at a range of concentrations of PSAT is shown in Figure 4. The voltage change at the test and control line for each concentration of total PSA was determined. Results were expressed as the mean ratio of the test/control line and were plotted against PSA concentration in ng/mL, see Figure 5. A linear response was observed for total PSA assays over the clinically relevant range 0.8–10 ng/mL with a limit of detection based on the IUAPC definition ×2 standard deviations of the negative control of 0.8 ng/mL. This is equivalent to previous data obtained for the quantification of PSA in solution using the RCM [26]. The graph shows a comparison of measurements made by optical means and using the RCM. The variability in individual data values (see standard deviation error bars) was much greater in the RCM measurements than in the scanning densitometer measurements. This probably relates to the positioning of the test and control lines in relation to the sensor coils. The sensitivity to changes in concentration of PSAT was greater using the RCM, this may be because this device quantifies all PMPs present within the entire test or control lines in contrast to the scanning densitometer which detects only those PMPs present at the surface of the strip. For PSAT quantification the sensitivity of the assay is very important, as even a modest increase in PSAT concentration over time can be indicative of disease progression [27].

Bottom Line: A detection limit of 0.8 ng/mL was achieved for total PSA using the RCM and is at clinically significant concentrations.The RCM has the potential to be modified to quantify multiple analytes in this format.This research shows promise for the development of an inexpensive device capable of quantifying multiple analytes at the point-of-care using a magneto-immunoassay in lateral flow format.

View Article: PubMed Central - PubMed

Affiliation: Institute of Bio-Sensing Technology, University of the West of England, Bristol, BS16 1QY, UK; E-Mails: jackie.barnett@uwe.ac.uk (J.M.B.); patrickwraith@blueyonder.co.uk (P.W.); janice.kiely@uwe.ac.uk (J.K.); hp@hphawkins.com (P.H.).

ABSTRACT
We describe the detection characteristics of a device the Resonant Coil Magnetometer (RCM) to quantify paramagnetic particles (PMPs) in immunochromatographic (lateral flow) assays. Lateral flow assays were developed using PMPs for the measurement of total prostate specific antigen (PSA) in serum samples. A detection limit of 0.8 ng/mL was achieved for total PSA using the RCM and is at clinically significant concentrations. Comparison of data obtained in a pilot study from the analysis of serum samples with commercially available immunoassays shows good agreement. The development of a quantitative magneto-immunoassay in lateral flow format for total PSA suggests the potential of the RCM to operate with many immunoassay formats. The RCM has the potential to be modified to quantify multiple analytes in this format. This research shows promise for the development of an inexpensive device capable of quantifying multiple analytes at the point-of-care using a magneto-immunoassay in lateral flow format.

No MeSH data available.